Olanzapine

• UNSPSC Description:

  Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptor (Ki=19 nM). Olanzapine is an atypical antipsychotic[1][2].

• Target Antigen:

  5-HT Receptor; Adrenergic Receptor; Apoptosis; Autophagy; Dopamine Receptor; mAChR; Mitophagy

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;GPCR/G Protein;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Olanzapine.html

• Solubility:

  DMSO : 20 mg/mL (ultrasonic)

• Smiles:

  CC1=CC(C(N2CCN(C)CC2)=N3)=C(S1)NC4=C3C=CC=C4

• Molecular Weight:

  312.442

• References & Citations:

  [1]APPROVED AGREED-UPON LABELING.|[2]Olanzapine for Injection, powder, for solution for intramuscular use.|[3]Vucicevic L, et al. Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine. Autophagy. 2014;10(12):2362-78.|[4]Karpel-Massler G, et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. J Neurooncol. 2015 Mar;122(1):21-33.|[5]Coccurello R, et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mousemodel of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl). 2006 Jul;186(4):561-71.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  132539-06-1